- $621.36m
- $603.55m
- $116.59m
Brief: JDS1, LLC terminates proxy contest at Catalyst’s 2022 annual meeting
Brief: Catalyst Biosciences Announces Withdrawal Of JDS1 Nominations To Board
Brief: Proxy Advisory Firms ISS And Glass Lewis Recommend Catalyst Stockholders Vote For All Of The Co's Nominees On The White Proxy Card
Brief: Catalyst Biosciences Inc Says Reached An Agreement With Jec II Associates Llc
Brief: Catalyst Biosciences Sends Letter To Stockholders
Brief: Catalyst Biosciences Comments On Favorable Delaware Court Of Chancery Ruling
U.S. STOCKS ON THE MOVE-EVgo, Microstrategy, Carnival Corp, Apple
U.S. STOCKS ON THE MOVE-2U Inc, General Mills, Tesla, Shopify
Catalyst Biosciences jumps on plans to return $65 million to stockholders
Brief: Catalyst Biosciences Announces Plan To Distribute Cash To Stockholders
Brief: Michael Torok Reports 8% Stake In Catalyst Biosciences Inc - SEC Filing
Brief: Julian Singer - On June 15, JDS1 Llc Filed A Complaint In The Delaware Court Of Chancery Against Catalyst Biosciences And Its Directors
Brief: Catalyst Biosciences Received Compliance Letter From Nasdaq Notifying Co It Has Regained Compliance With Minimum Bid Price Requirement
Brief: Jds1 Llc - Calls Upon Catalyst Biosciences To Schedule 2022 Annual Meeting And Fix The Associated Record Date Therefor
Catalyst Bio more than doubles on $60 mln asset sale to Vertex
Brief: Catalyst Biosciences Sells Complement Portfolio For $60 Million
Brief: Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
Catalyst Biosciences Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: Julian Singer Says JDS1 LLC Filed Complaint Against Catalyst Biosciences In Delaware Court Of Chancery